Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Donna Tjandra¹  Alzheimer's Disease Neuroimaging Initiative¹  Devendra Goyal¹  Jenna Wiens¹  Bruno Giordani²  Raymond Q. Migrino³  Zeeshan Syed⁴ 

[1] Computer Science and EngineeringUniversity of MichiganAnn ArborMIUSA;Neuropsychology Section, Department of PsychiatryUniversity of MichiganAnn ArborMIUSA;Phoenix Veterans Affairs Health Care SystemPhoenixAZUSA;School of Medicine, Stanford UniversityStanfordCAUSA;

关键词: Machine learning;    Trajectory;    Longitudinal;    Staging;    Biomarkers;   

DOI  :  10.1016/j.dadm.2018.06.007

来源: DOAJ

【 摘 要 】

Abstract Introduction Models characterizing intermediate disease stages of Alzheimer's disease (AD) are needed to inform clinical care and prognosis. Current models, however, use only a small subset of available biomarkers, capturing only coarse changes along the complete spectrum of disease progression. We propose the use of machine learning techniques and clinical, biochemical, and neuroimaging biomarkers to characterize progression to AD. Methods We used a large multimodal longitudinal data set of biomarkers and demographic and genotype information from 1624 participants from the Alzheimer's Disease Neuroimaging Initiative. Using hidden Markov models, we characterized intermediate disease stages. We validated inferred disease trajectories by comparing time to first clinical AD diagnosis. We trained an L2‐regularized logistic regression model to predict disease trajectory and evaluated its discriminative performance on a test set. Results We identified 12 distinct disease states. Progression to AD occurred most often through one of two possible paths through these states. Paths differed in terms of rate of disease progression (by 5.44 years on average), amyloid and total‐tau (t‐tau) burden (by 10% and 69%, respectively), and hippocampal neurodegeneration (P < .001). On the test set, the predictive model achieved an area under the receiver operating characteristic curve of 0.85. Discussion Progression to AD, in terms of biomarker trajectories, can be predicted based on participant‐specific factors. Such disease staging tools could help in targeting high‐risk patients for therapeutic intervention trials. As longitudinal data with richer features are collected, such models will help increase our understanding of the factors that drive the different trajectories of AD.

【 授权许可】

Unknown